Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with conventional NHL or ALL regimens, but has improved with dose‐intensive regimens. METHODS To eva...
Saved in:
Published in | Cancer Vol. 106; no. 7; pp. 1569 - 1580 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.04.2006
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND
Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with conventional NHL or ALL regimens, but has improved with dose‐intensive regimens.
METHODS
To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B‐ALL, 31 patients with newly diagnosed BL or B‐ALL received the hyper‐fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m2 was given on Days 1 and 11 of hyper‐CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses.
RESULTS
Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3‐year overall survival (OS), event‐free survival, and disease‐free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3‐year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper‐CVAD alone) groups identified age and treatment with rituximab as favorable factors.
CONCLUSIONS
The addition of rituximab to hyper‐CVAD may improve outcome in adult BL or B‐ALL, particularly in elderly patients. Cancer 2006. © 2006 American Cancer Society.
The addition of rituximab to hyper‐CVAD may improve outcome in adult Burkitt lymphoma and acute lymphoblastic leukemia, particularly in elderly patients. |
---|---|
AbstractList | Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens.
To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B-ALL, 31 patients with newly diagnosed BL or B-ALL received the hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m(2) was given on Days 1 and 11 of hyper-CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses.
Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3-year overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3-year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper-CVAD alone) groups identified age and treatment with rituximab as favorable factors.
The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients. BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with conventional NHL or ALL regimens, but has improved with dose‐intensive regimens. METHODS To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B‐ALL, 31 patients with newly diagnosed BL or B‐ALL received the hyper‐fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m2 was given on Days 1 and 11 of hyper‐CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses. RESULTS Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3‐year overall survival (OS), event‐free survival, and disease‐free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3‐year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper‐CVAD alone) groups identified age and treatment with rituximab as favorable factors. CONCLUSIONS The addition of rituximab to hyper‐CVAD may improve outcome in adult BL or B‐ALL, particularly in elderly patients. Cancer 2006. © 2006 American Cancer Society. The addition of rituximab to hyper‐CVAD may improve outcome in adult Burkitt lymphoma and acute lymphoblastic leukemia, particularly in elderly patients. Abstract BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B‐ALL has been poor with conventional NHL or ALL regimens, but has improved with dose‐intensive regimens. METHODS To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B‐ALL, 31 patients with newly diagnosed BL or B‐ALL received the hyper‐fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m 2 was given on Days 1 and 11 of hyper‐CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses. RESULTS Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3‐year overall survival (OS), event‐free survival, and disease‐free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3‐year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper‐CVAD alone) groups identified age and treatment with rituximab as favorable factors. CONCLUSIONS The addition of rituximab to hyper‐CVAD may improve outcome in adult BL or B‐ALL, particularly in elderly patients. Cancer 2006. © 2006 American Cancer Society. The addition of rituximab to hyper‐CVAD may improve outcome in adult Burkitt lymphoma and acute lymphoblastic leukemia, particularly in elderly patients. |
Author | O'Brien, Susan Garcia‐Manero, Guillermo Kantarjian, Hagop Bueso‐Ramos, Carlos Verstovsek, Srdan Giles, Francis J. Pierce, Sherry A. Brandt, Mark Cortes, Jorge Wierda, William G. Faderl, Stefan Cabanillas, Fernando Keating, Michael J. Thomas, Deborah A. Shan, Jianqin Hagemeister, Fredrick B. |
Author_xml | – sequence: 1 givenname: Deborah A. surname: Thomas fullname: Thomas, Deborah A. – sequence: 2 givenname: Stefan surname: Faderl fullname: Faderl, Stefan – sequence: 3 givenname: Susan surname: O'Brien fullname: O'Brien, Susan – sequence: 4 givenname: Carlos surname: Bueso‐Ramos fullname: Bueso‐Ramos, Carlos – sequence: 5 givenname: Jorge surname: Cortes fullname: Cortes, Jorge – sequence: 6 givenname: Guillermo surname: Garcia‐Manero fullname: Garcia‐Manero, Guillermo – sequence: 7 givenname: Francis J. surname: Giles fullname: Giles, Francis J. – sequence: 8 givenname: Srdan surname: Verstovsek fullname: Verstovsek, Srdan – sequence: 9 givenname: William G. surname: Wierda fullname: Wierda, William G. – sequence: 10 givenname: Sherry A. surname: Pierce fullname: Pierce, Sherry A. – sequence: 11 givenname: Jianqin surname: Shan fullname: Shan, Jianqin – sequence: 12 givenname: Mark surname: Brandt fullname: Brandt, Mark – sequence: 13 givenname: Fredrick B. surname: Hagemeister fullname: Hagemeister, Fredrick B. – sequence: 14 givenname: Michael J. surname: Keating fullname: Keating, Michael J. – sequence: 15 givenname: Fernando surname: Cabanillas fullname: Cabanillas, Fernando – sequence: 16 givenname: Hagop surname: Kantarjian fullname: Kantarjian, Hagop email: hkantarj@mdanderson.org |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17645718$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16502413$$D View this record in MEDLINE/PubMed |
BookMark | eNp90EtO3TAUBmCrApULdNIFVJ50ghRqJ36EIQ0tICEqIUDMIsc5VlziJLIdQWZdQsUSuxIM9yJmHfmhz_-R_120NYwDIPSZkkNKSP5ND9of5lRK8QGtKDmSGaEs30IrQkiZcVbc7aDdEH6no8x58RHtUMFJzmixQk9VB260zs3DGDvwalrwg40d7pYJ_L8_f6vb4xM89XPA3sb50TrVYDN6nDCOHlR0MEQ8GqzauY_4--zvbYxYDe3bPoXEFIb7xU3d6BROr5We49tN06sQrcY9zPfgrNpH20b1AT5t1j108_PHdXWWXfw6Pa-OLzJdcCkyowlXOTAmSgm60Q0pKQOmy7xkhpIWBGWygbbgXBshj0QLnLVM5FwZKktT7KGDda72YwgeTD359D2_1JTUL8XWL8XWr8Um_GWNp7lx0L7TTZMJfN0AFbTqjVeDtuHdScG4pGVydO0ebA_Lf0bW1WV1tR7-DECnl_o |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1111_imm_12281 crossref_primary_10_1016_j_clml_2014_12_010 crossref_primary_10_1182_asheducation_2007_1_297 crossref_primary_10_1002_cncr_23655 crossref_primary_10_1200_JGO_2015_002378 crossref_primary_10_1097_MPH_0b013e318282cef5 crossref_primary_10_3324_haematol_2020_278181 crossref_primary_10_1002_cncr_24862 crossref_primary_10_1200_JCO_2009_23_8527 crossref_primary_10_1080_10428194_2017_1317091 crossref_primary_10_1111_j_1365_2141_2010_08447_x crossref_primary_10_1080_10428194_2019_1623884 crossref_primary_10_1517_13543784_2012_679359 crossref_primary_10_1007_s00277_018_3473_8 crossref_primary_10_1002_cncr_32139 crossref_primary_10_1182_blood_2006_08_043646 crossref_primary_10_1016_j_tet_2024_133980 crossref_primary_10_1097_MOH_0b013e3283034697 crossref_primary_10_1111_j_1365_2141_2011_08947_x crossref_primary_10_1007_s00277_013_1771_8 crossref_primary_10_1093_annonc_mdt058 crossref_primary_10_2169_internalmedicine_50_4860 crossref_primary_10_1002_cyto_b_22113 crossref_primary_10_1182_bloodadvances_2016000042 crossref_primary_10_1111_j_1601_0825_2009_01586_x crossref_primary_10_1007_s11805_010_0504_1 crossref_primary_10_1002_ajh_23886 crossref_primary_10_1016_j_clml_2019_06_011 crossref_primary_10_3816_CLM_2007_s_034 crossref_primary_10_1097_MOP_0000000000000564 crossref_primary_10_1016_S0140_6736_11_61177_X crossref_primary_10_1002_cncr_30624 crossref_primary_10_1080_10428194_2022_2027402 crossref_primary_10_1007_s12032_009_9213_0 crossref_primary_10_3919_jjsa_73_921 crossref_primary_10_1158_0008_5472_CAN_10_2238 crossref_primary_10_1056_NEJMcpc1209274 crossref_primary_10_1179_102453312X13336169155538 crossref_primary_10_3109_10428194_2012_679267 crossref_primary_10_1016_j_apradiso_2016_07_016 crossref_primary_10_1016_j_prp_2013_11_009 crossref_primary_10_1016_j_leukres_2017_09_020 crossref_primary_10_1002_pbc_21388 crossref_primary_10_1002_pbc_24416 crossref_primary_10_1016_j_dld_2022_08_037 crossref_primary_10_1080_10428194_2019_1605071 crossref_primary_10_35509_01239015_892 crossref_primary_10_1007_s12288_012_0216_1 crossref_primary_10_1038_bmt_2009_295 crossref_primary_10_2169_internalmedicine_52_0604 crossref_primary_10_1007_s00277_008_0488_6 crossref_primary_10_1182_bloodadvances_2017008748 crossref_primary_10_5858_2008_132_462_ALIASD crossref_primary_10_1002_ajh_24720 crossref_primary_10_1182_asheducation_2011_1_243 crossref_primary_10_1016_j_beha_2012_01_005 crossref_primary_10_1155_2010_516047 crossref_primary_10_1016_j_beha_2012_01_003 crossref_primary_10_5649_jjphcs_45_285 crossref_primary_10_1177_1078155218820105 crossref_primary_10_1124_pr_118_016972 crossref_primary_10_1007_s40265_013_0026_2 crossref_primary_10_1186_s13256_020_02449_y crossref_primary_10_1007_s12185_009_0444_9 crossref_primary_10_1007_s11899_016_0326_1 crossref_primary_10_1155_2013_412368 crossref_primary_10_1200_JCO_2009_26_9456 crossref_primary_10_1080_08998280_2020_1747835 crossref_primary_10_1111_j_1365_2141_2007_06634_x crossref_primary_10_1182_blood_2015_01_623900 crossref_primary_10_33590_emjhematol_10312198 crossref_primary_10_1053_j_seminoncol_2009_07_009 crossref_primary_10_1002_cncr_23522 crossref_primary_10_1038_leu_2009_102 crossref_primary_10_1007_s00277_023_05328_w crossref_primary_10_1155_2012_735392 crossref_primary_10_2169_internalmedicine_50_5815 crossref_primary_10_1002_ajh_23187 crossref_primary_10_3109_10428194_2011_559668 crossref_primary_10_3919_jjsa_76_539 crossref_primary_10_2217_ijh_12_25 crossref_primary_10_1517_14656560802618746 crossref_primary_10_1080_1120009X_2018_1535771 crossref_primary_10_1080_14656566_2016_1250884 crossref_primary_10_3109_10428194_2011_619019 crossref_primary_10_1016_S2152_2650_21_01221_0 crossref_primary_10_1056_NEJMra2025746 crossref_primary_10_1182_blood_2009_07_232124 crossref_primary_10_4044_joma_126_143 crossref_primary_10_1016_j_clml_2022_06_002 crossref_primary_10_1111_bjh_13205 crossref_primary_10_1182_blood_2008_03_145128 crossref_primary_10_1007_s44178_023_00063_8 crossref_primary_10_1016_j_beha_2018_07_013 crossref_primary_10_1016_j_leukres_2007_11_036 crossref_primary_10_1007_s11899_010_0064_8 crossref_primary_10_1182_blood_2006_10_051912 crossref_primary_10_24060_2076_3093_2022_12_4_320_327 crossref_primary_10_1186_1757_1626_1_15 crossref_primary_10_1182_bloodadvances_2018029199 crossref_primary_10_3390_ph13010016 crossref_primary_10_1002_cncr_31522 crossref_primary_10_1007_s11899_017_0380_3 crossref_primary_10_1016_j_clml_2013_11_010 crossref_primary_10_1016_j_leukres_2014_12_016 crossref_primary_10_3960_jslrt_53_167 crossref_primary_10_3389_fphar_2021_760013 crossref_primary_10_1056_NEJMoa1609783 crossref_primary_10_1136_bcr_2020_240925 crossref_primary_10_1200_JOP_18_00148 crossref_primary_10_1007_s11899_019_00503_1 crossref_primary_10_1016_j_clon_2016_09_004 crossref_primary_10_1111_tid_12254 crossref_primary_10_1182_asheducation_2008_1_341 crossref_primary_10_3892_ol_2019_11155 crossref_primary_10_1111_bjh_12585 crossref_primary_10_3109_10428194_2012_715346 crossref_primary_10_1097_RLU_0b013e3181a34552 crossref_primary_10_1093_annonc_mdt414 crossref_primary_10_1179_joc_2007_19_2_236 crossref_primary_10_1038_leu_2010_157 crossref_primary_10_1053_j_seminoncol_2009_02_003 crossref_primary_10_1200_JCO_20_00303 crossref_primary_10_1111_j_1365_2141_2011_08877_x crossref_primary_10_1111_j_1365_2141_2010_08246_x crossref_primary_10_1038_sj_onc_1210376 crossref_primary_10_1002_cncr_32606 crossref_primary_10_3816_CLM_2009_s_017 crossref_primary_10_1080_10428194_2020_1747068 crossref_primary_10_1038_bmt_2012_129 crossref_primary_10_1002_cncr_33933 crossref_primary_10_1177_2040620719849496 crossref_primary_10_1186_s40001_014_0082_4 crossref_primary_10_1186_s13045_020_00905_2 crossref_primary_10_1097_MPH_0000000000001419 crossref_primary_10_3816_CLML_2011_n_007 crossref_primary_10_1158_1078_0432_CCR_06_2294 crossref_primary_10_1016_S1931_6925_12_60038_2 crossref_primary_10_1136_bcr_2017_220313 crossref_primary_10_3390_lymphatics1020010 crossref_primary_10_1182_blood_2023020168 crossref_primary_10_1186_s13045_019_0703_z crossref_primary_10_1002_cncr_27482 crossref_primary_10_1016_j_hoc_2008_07_009 crossref_primary_10_1080_10428190701882948 crossref_primary_10_1055_s_0043_1768177 crossref_primary_10_1016_j_blre_2011_08_001 crossref_primary_10_35509_01239015_690 crossref_primary_10_1093_jnci_dju300 crossref_primary_10_1007_s11912_007_0064_6 crossref_primary_10_3324_haematol_2020_270876 crossref_primary_10_1016_j_pop_2016_07_012 crossref_primary_10_1186_2162_3619_1_28 crossref_primary_10_1200_JCO_2012_41_6768 crossref_primary_10_1002_2211_5463_12538 crossref_primary_10_1016_j_uct_2007_08_001 crossref_primary_10_1016_S2152_2650_21_01193_9 crossref_primary_10_1038_leu_2008_344 crossref_primary_10_3390_jcm12041451 crossref_primary_10_1016_j_bbmt_2010_08_001 crossref_primary_10_1016_j_leukres_2019_106287 crossref_primary_10_1016_j_amjmed_2016_05_028 crossref_primary_10_1177_1010428319901061 crossref_primary_10_1182_blood_2015_05_645721 crossref_primary_10_1016_j_path_2010_09_010 crossref_primary_10_1007_s00277_015_2427_7 crossref_primary_10_1016_j_critrevonc_2015_12_007 crossref_primary_10_1007_s11899_010_0076_4 crossref_primary_10_1097_PAT_0b013e3283634dec crossref_primary_10_1016_j_lrr_2023_100401 crossref_primary_10_1200_JCO_20_03288 crossref_primary_10_1080_10428190802503377 crossref_primary_10_1007_s11912_020_0898_8 crossref_primary_10_1159_000334705 crossref_primary_10_1016_j_hoc_2016_07_009 crossref_primary_10_1097_MOH_0b013e3281bccdee crossref_primary_10_3109_10428190903308031 crossref_primary_10_1002_cncr_27918 crossref_primary_10_3109_10428194_2011_593274 crossref_primary_10_1016_j_leukres_2011_11_010 crossref_primary_10_1111_ajco_13780 crossref_primary_10_2119_molmed_2015_00210 crossref_primary_10_1002_cncr_25319 crossref_primary_10_1111_bjh_12556 crossref_primary_10_1186_s40364_019_0160_4 crossref_primary_10_2165_00044011_200929080_00001 crossref_primary_10_1182_blood_2014_08_596403 crossref_primary_10_1002_jha2_501 crossref_primary_10_1002_ajh_22165 crossref_primary_10_2217_fon_09_74 crossref_primary_10_1080_10428194_2017_1413186 crossref_primary_10_1111_bjh_15262 crossref_primary_10_1182_blood_2020006926 crossref_primary_10_1016_j_clml_2018_02_013 crossref_primary_10_1200_JCO_2009_25_6990 crossref_primary_10_3389_fonc_2022_1063689 crossref_primary_10_1002_ajh_21998 crossref_primary_10_1182_blood_2009_03_213231 crossref_primary_10_1016_S1470_2045_11_70386_2 crossref_primary_10_1080_10428190601142831 crossref_primary_10_1016_j_medcle_2018_05_014 crossref_primary_10_1158_1535_7163_MCT_13_0044 crossref_primary_10_1016_j_leukres_2008_07_024 crossref_primary_10_1155_2011_780839 crossref_primary_10_1016_S1470_2045_18_30011_1 crossref_primary_10_1080_10428194_2019_1654097 crossref_primary_10_1021_acs_jnatprod_2c00673 crossref_primary_10_1016_j_aidm_2014_03_007 crossref_primary_10_1002_cncr_28264 crossref_primary_10_3109_10428194_2015_1085529 crossref_primary_10_1111_ejh_12408 crossref_primary_10_1182_blood_2008_04_151860 crossref_primary_10_1007_s12094_008_0270_1 crossref_primary_10_1159_000351172 crossref_primary_10_1586_14737140_2014_866042 crossref_primary_10_1186_1471_2407_14_71 crossref_primary_10_3389_fonc_2022_838817 crossref_primary_10_1200_JCO_2009_26_0398 crossref_primary_10_3389_fonc_2019_00109 crossref_primary_10_3904_kjim_2022_401 crossref_primary_10_1016_j_annonc_2023_09_3112 crossref_primary_10_1002_cam4_1513 crossref_primary_10_1007_s11899_009_0022_5 crossref_primary_10_1016_j_ijid_2010_03_025 crossref_primary_10_1016_j_mayocp_2016_09_010 crossref_primary_10_1080_10428190701411441 crossref_primary_10_1182_bloodadvances_2023010223 crossref_primary_10_1186_s12906_020_2879_8 crossref_primary_10_1016_j_beha_2014_10_006 crossref_primary_10_1155_2012_403648 crossref_primary_10_1016_j_beha_2020_101226 crossref_primary_10_1158_0008_5472_CAN_06_4642 crossref_primary_10_1002_cam4_1870 crossref_primary_10_1182_blood_2014_06_538504 crossref_primary_10_1159_000375258 crossref_primary_10_1182_blood_2007_05_038950 crossref_primary_10_1157_13116574 crossref_primary_10_1007_s11899_008_0024_8 crossref_primary_10_1182_blood_2009_04_214627 crossref_primary_10_1186_s13045_023_01409_5 crossref_primary_10_1002_cncr_28136 crossref_primary_10_1002_cncr_31669 crossref_primary_10_3390_ph3103258 crossref_primary_10_1007_s11899_014_0202_9 crossref_primary_10_1007_s11864_021_00857_w crossref_primary_10_1016_j_blre_2014_06_004 crossref_primary_10_3390_cancers14174290 crossref_primary_10_1002_hon_754 crossref_primary_10_1111_bjh_13628 crossref_primary_10_1016_j_coms_2008_06_009 crossref_primary_10_4143_crt_2014_055 crossref_primary_10_1097_MOP_0b013e3282f572b6 crossref_primary_10_1111_bjh_16207 crossref_primary_10_1016_j_hoc_2019_04_001 crossref_primary_10_1093_annonc_mdl393 crossref_primary_10_1158_1078_0432_CCR_15_0125 crossref_primary_10_1371_journal_pone_0027988 crossref_primary_10_7759_cureus_34950 crossref_primary_10_3390_ijms25126314 crossref_primary_10_1097_CCO_0b013e32834bb88e crossref_primary_10_1080_14712598_2018_1425389 crossref_primary_10_1182_asheducation_2006_1_133 crossref_primary_10_1177_2040620716652289 crossref_primary_10_3960_jslrt_51_109 crossref_primary_10_1182_blood_2009_08_231613 crossref_primary_10_1016_j_medcli_2017_11_037 crossref_primary_10_3919_jjsa_75_457 crossref_primary_10_1002_jha2_3 crossref_primary_10_1186_s13256_018_1828_3 crossref_primary_10_1007_s11899_007_0023_1 crossref_primary_10_1111_bjh_13040 crossref_primary_10_1002_cncr_28194 crossref_primary_10_1016_S0140_6736_15_01317_3 crossref_primary_10_1111_j_1365_2141_2008_07513_x crossref_primary_10_1182_bloodadvances_2023009731 crossref_primary_10_1093_annonc_mdq677 crossref_primary_10_1097_MOP_0b013e3282f424b0 crossref_primary_10_1007_s11899_006_0004_9 crossref_primary_10_1007_s11899_008_0020_z crossref_primary_10_3960_jslrt_20016 crossref_primary_10_1038_nrd2240 crossref_primary_10_1002_cncr_30037 crossref_primary_10_1182_blood_2006_12_062927 crossref_primary_10_1021_bc900128h crossref_primary_10_1007_s12185_021_03132_8 crossref_primary_10_1182_asheducation_2017_1_259 crossref_primary_10_1002_pbc_21753 crossref_primary_10_1016_j_clml_2023_01_013 crossref_primary_10_1007_s11899_015_0263_4 crossref_primary_10_1111_bjh_16425 crossref_primary_10_1002_path_2669 crossref_primary_10_1002_cncr_25008 crossref_primary_10_1182_blood_2011_11_390781 crossref_primary_10_3389_fonc_2014_00082 crossref_primary_10_3109_0284186X_2015_1054951 crossref_primary_10_1002_cncr_33655 crossref_primary_10_1007_s00277_009_0729_3 crossref_primary_10_1182_blood_2006_10_051771 crossref_primary_10_4143_crt_2020_1060 crossref_primary_10_1111_j_1365_2559_2008_02974_x crossref_primary_10_1186_s12902_018_0312_9 crossref_primary_10_2147_BLCTT_S407804 crossref_primary_10_1016_j_bbmt_2012_11_016 crossref_primary_10_1182_asheducation_2016_1_589 crossref_primary_10_1177_01945998211041533 crossref_primary_10_3109_10428194_2013_844342 crossref_primary_10_1007_s00277_012_1531_1 crossref_primary_10_1097_QAI_0b013e31802bb5d0 crossref_primary_10_4264_numa_74_5_213 crossref_primary_10_1002_cncr_29383 crossref_primary_10_1182_blood_2012_12_475558 crossref_primary_10_1111_bjh_17862 crossref_primary_10_1007_s00280_024_04687_z crossref_primary_10_2217_imt_15_108 crossref_primary_10_3233_HAB_211511 crossref_primary_10_1002_ajh_22189 crossref_primary_10_1007_s12288_017_0901_1 crossref_primary_10_1016_j_hoc_2009_07_004 crossref_primary_10_1016_j_hoc_2009_07_005 crossref_primary_10_1016_j_leukres_2007_02_015 crossref_primary_10_1182_blood_2014_03_563627 crossref_primary_10_1186_1471_2407_10_560 crossref_primary_10_1002_cncr_26433 crossref_primary_10_1053_j_seminhematol_2008_09_009 crossref_primary_10_2169_naika_97_1602 crossref_primary_10_1089_apc_2007_0124 crossref_primary_10_1016_S2152_2650_23_00308_7 crossref_primary_10_1177_107327481302000108 crossref_primary_10_1016_j_clml_2021_03_012 crossref_primary_10_1053_j_seminhematol_2008_09_004 crossref_primary_10_1002_pbc_21857 crossref_primary_10_1053_j_seminhematol_2008_09_003 crossref_primary_10_1111_bjh_12736 crossref_primary_10_1177_2040620713514682 crossref_primary_10_3390_ph9020028 crossref_primary_10_1182_blood_2020008374 crossref_primary_10_1177_20406207221112900 crossref_primary_10_3390_jpm11080715 crossref_primary_10_1186_1750_9378_8_37 crossref_primary_10_1186_s40164_019_0152_y crossref_primary_10_1007_s12185_010_0728_0 crossref_primary_10_3390_cancers16071397 crossref_primary_10_1016_j_clml_2012_12_003 crossref_primary_10_1080_16078454_2022_2074704 crossref_primary_10_1007_s00277_008_0645_y crossref_primary_10_3390_cancers13164079 crossref_primary_10_3892_ol_2017_5583 crossref_primary_10_1002_cncr_22632 crossref_primary_10_1182_blood_2019004099 crossref_primary_10_3816_CLM_2009_n_060 crossref_primary_10_1007_s12254_009_0115_9 crossref_primary_10_21320_2500_2139_2016_9_4_420_437 crossref_primary_10_1016_S1155_1984_07_47144_8 crossref_primary_10_4137_CMO_S7262 crossref_primary_10_1007_s12094_008_0193_x crossref_primary_10_1007_s11899_013_0160_7 crossref_primary_10_1200_JCO_2009_26_6791 crossref_primary_10_1155_2019_7313706 crossref_primary_10_1007_s11864_022_01032_5 crossref_primary_10_1007_s11899_016_0316_3 |
Cites_doi | 10.1038/sj.leu.2401910 10.1200/JCO.1986.4.12.1732 10.1182/blood.V87.2.495.bloodjournal872495 10.1080/01621459.1958.10501452 10.1200/JCO.2005.12.051 10.1056/NEJM199309303291402 10.1182/blood-2004-02-0405 10.1200/JCO.1996.14.9.2465 10.1182/blood.V91.11.3995 10.1093/annonc/mdf253 10.1182/blood.V90.10.3844 10.1182/blood.V104.11.2732.2732 10.1111/j.1365-2141.2004.04925.x 10.1200/JCO.1991.9.1.123 10.1182/blood.V80.10.2471.2471 10.1200/JCO.1990.8.6.994 10.1002/cncr.10365 10.1093/annonc/8.suppl_1.S77 10.1200/JCO.2001.19.8.2153 10.1200/JCO.1998.16.8.2825 10.1200/JCO.2001.19.8.2165 10.1200/JCO.1999.17.8.2461 10.1111/j.1365-2141.2004.05141.x 10.1200/JCO.2001.19.2.389 10.1111/j.1365-2141.1976.tb03563.x 10.1182/blood.V85.3.664.bloodjournal853664 10.1038/sj.cdd.4400688 10.1182/blood.V63.5.1102.1102 10.1200/JCO.1996.14.4.1252 10.1056/NEJMoa011795 10.1002/cncr.20143 10.1200/JCO.1995.13.2.359 |
ContentType | Journal Article |
Copyright | Copyright © 2006 American Cancer Society 2006 INIST-CNRS Copyright 2006 American Cancer Society. |
Copyright_xml | – notice: Copyright © 2006 American Cancer Society – notice: 2006 INIST-CNRS – notice: Copyright 2006 American Cancer Society. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1002/cncr.21776 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 1580 |
ExternalDocumentID | 10_1002_cncr_21776 16502413 17645718 CNCR21776 |
Genre | article Clinical Trial Journal Article |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AARRQ AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 08R AAJUZ AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS AI. AKALU EMOBN HF~ H~9 IQODW LMP RSU RYL VH1 WHG XFK Y6R YQJ ZA5 ZXP CGR CUY CVF ECM EIF NPM AAQOH AAYXX CITATION |
ID | FETCH-LOGICAL-c3576-fc05a2e44687ecbcb0814e4c8284f10de6147bed355cf6796de54d4625af178f3 |
IEDL.DBID | DR2 |
ISSN | 0008-543X |
IngestDate | Fri Aug 23 02:13:02 EDT 2024 Sat Sep 28 07:47:43 EDT 2024 Sun Oct 22 16:06:47 EDT 2023 Sat Aug 24 01:04:09 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Antineoplastic agent B-ALL chemoimmunotherapy BL Monoclonal antibody Glucocorticoid Doxorubicin Alkaloid Isomerases Cancerology Lymphoproliferative syndrome Immunotherapy Anticytokine Adult Acute lymphocytic leukemia Antimitotic Human Corticosteroid DNA topoisomerase (ATP-hydrolysing) Drug combination Dexamethasone Enzyme Acute Burkitt lymphoma Enzyme inhibitor Acute leukemia Rituximab Malignant hemopathy Non Hodgkin lymphoma Vincristine Fractionated dose Infection Alkylating agent Antibiotic Oxazaphosphinane derivatives Chemotherapy Cyclophosphamide acute lymphoblastic leukemia Nitrogen mustard Viral disease adult Burkitt lymphoma Anthracyclins Combined treatment Therapeutic protocol hyper-CVAD |
Language | English |
License | CC BY 4.0 Copyright 2006 American Cancer Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3576-fc05a2e44687ecbcb0814e4c8284f10de6147bed355cf6796de54d4625af178f3 |
Notes | Fax: (713) 794‐4297 |
PMID | 16502413 |
PageCount | 12 |
ParticipantIDs | crossref_primary_10_1002_cncr_21776 pubmed_primary_16502413 pascalfrancis_primary_17645718 wiley_primary_10_1002_cncr_21776_CNCR21776 |
PublicationCentury | 2000 |
PublicationDate | 1 April 2006 |
PublicationDateYYYYMMDD | 2006-04-01 |
PublicationDate_xml | – month: 04 year: 2006 text: 1 April 2006 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2006 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | 2004; 100 1984; 63 1992; 80 1965; 53 2004; 104 2004; 126 1993; 329 2004; 125 2002; 94 1995; 13 2002; 13 2000; 7 2002 1991 1996; 14 1992; 34 1991; 9 2005; 23 1966; 50 1991; 5 1997; 8 1998; 16 1995; 85 1997; 90 1976; 33 2000; 14 1999; 17 1986; 4 2002; 100 2001; 19 2003; 2 1994; 99 2002; 346 1998; 91 1972; 34 1990; 8 1996; 87 e_1_2_5_26_2 e_1_2_5_27_2 Gladstone B (e_1_2_5_6_2) 1994; 99 e_1_2_5_25_2 Bernasconi C (e_1_2_5_8_2) 1991; 5 e_1_2_5_22_2 e_1_2_5_23_2 e_1_2_5_21_2 e_1_2_5_42_2 e_1_2_5_28_2 Todeschini G (e_1_2_5_20_2) 1997; 8 e_1_2_5_29_2 Jazirehi AR (e_1_2_5_36_2) 2003; 2 e_1_2_5_41_2 e_1_2_5_40_2 Thomas DA (e_1_2_5_3_2) 2002 e_1_2_5_14_2 e_1_2_5_37_2 e_1_2_5_13_2 Fleming TR (e_1_2_5_33_2) 1991 e_1_2_5_16_2 e_1_2_5_35_2 e_1_2_5_15_2 e_1_2_5_7_2 e_1_2_5_5_2 e_1_2_5_12_2 Mantel N (e_1_2_5_32_2) 1966; 50 e_1_2_5_4_2 e_1_2_5_11_2 e_1_2_5_2_2 Kantarjian HM (e_1_2_5_10_2) 1990; 8 e_1_2_5_18_2 e_1_2_5_17_2 e_1_2_5_39_2 e_1_2_5_19_2 Kaplan EL (e_1_2_5_31_2) 1965; 53 Hoelzer D (e_1_2_5_38_2) 2004; 104 Ostronoff M (e_1_2_5_9_2) 1992; 34 e_1_2_5_30_2 Hoelzer D (e_1_2_5_24_2) 2002; 100 Cox DR (e_1_2_5_34_2) 1972; 34 |
References_xml | – volume: 50 start-page: 163 year: 1966 end-page: 170 article-title: Evaluation of survival data and two new rank order statistics arising in its consideration publication-title: J R Stat Soc. – volume: 104 year: 2004 article-title: Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) publication-title: Blood. – volume: 14 start-page: 1252 year: 1996 end-page: 1261 article-title: Improved survival for children with B‐cell acute lymphoblastic leukemia and stage IV small noncleaved‐cell lymphoma: a pediatric oncology group study publication-title: J Clin Oncol. – volume: 19 start-page: 389 year: 2001 end-page: 397 article-title: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non‐Hodgkin's lymphoma publication-title: J Clin Oncol. – volume: 87 start-page: 495 year: 1996 end-page: 508 article-title: Improved outcome in adult B‐cell acute lymphoblastic leukemia publication-title: Blood. – volume: 19 start-page: 2165 year: 2001 end-page: 2170 article-title: Rituximab dose‐escalation trial in chronic lymphocytic leukemia publication-title: J Clin Oncol. – volume: 63 start-page: 1102 year: 1984 end-page: 1111 article-title: An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults publication-title: Blood. – volume: 85 start-page: 664 year: 1995 end-page: 674 article-title: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols publication-title: Blood. – volume: 126 start-page: 815 year: 2004 end-page: 820 article-title: High response rate and manageable toxicity with an intensive, short‐term chemotherapy programme for Burkitt's lymphoma in adults publication-title: Br J Haematol. – start-page: 152 year: 2002 end-page: 197 – volume: 91 start-page: 3995 year: 1998 end-page: 4019 article-title: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia publication-title: Blood. – volume: 8 start-page: 77 issue: suppl 1 year: 1997 end-page: 81 article-title: Eighty‐one percent event‐free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol publication-title: Ann Oncol. – volume: 4 start-page: 1732 year: 1986 end-page: 1739 article-title: Results of treatment of advanced‐stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high‐dose fractionated cyclophosphamide and coordinated high‐dose methotrexate and cytarabine publication-title: J Clin Oncol. – volume: 34 start-page: 389 year: 1992 end-page: 397 article-title: Burkitt's lymphoma in adults: a retrospective study of 46 cases publication-title: Nouv Rev Fr Hematol. – volume: 100 start-page: 1438 year: 2004 end-page: 1448 article-title: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251 publication-title: Cancer. – volume: 94 start-page: 1492 year: 2002 end-page: 1499 article-title: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome‐related Burkitt lymphoma/leukemia publication-title: Cancer. – volume: 125 start-page: 414 year: 2004 end-page: 415 article-title: Rituximab in three children with relapsed/refractory B‐cell acute lymphoblastic leukaemia/Burkitt non‐Hodgkin's lymphoma publication-title: Br J Haematol. – volume: 13 start-page: 359 year: 1995 end-page: 372 article-title: Non‐Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin‐Frankfurt‐Munster Group publication-title: J Clin Oncol. – volume: 17 start-page: 2461 year: 1999 end-page: 2470 article-title: Hyper‐CVAD program in Burkitt's‐type adult acute lymphoblastic leukemia publication-title: J Clin Oncol. – volume: 5 start-page: 90 issue: suppl 1 year: 1991 end-page: 94 article-title: Burkitt's lymphoma/leukemia: a clinicopathologic study on 24 adult patients publication-title: Leukemia. – volume: 7 start-page: 574 year: 2000 end-page: 586 article-title: Susceptibility to drug‐induced apoptosis correlates with differential modulation of Bad, Bcl‐2 and Bcl‐xL protein levels publication-title: Cell Death Differ. – volume: 104 start-page: 3009 year: 2004 end-page: 3020 article-title: Adult Burkitt leukemia and lymphoma publication-title: Blood. – volume: 99 start-page: 264 year: 1994 end-page: 266 article-title: Cytogenetic studies on patients of acute lymphoblastic leukemia Burkitt's type with (8;14) & (14;18) translocations publication-title: Indian J Med Res. – volume: 2 start-page: 1183 year: 2003 end-page: 1193 article-title: Rituximab (anti‐CD20) selectively modifies Bcl‐xL and apoptosis protease activating factor‐1 (Apaf‐1) expression and sensitizes human non‐Hodgkin's lymphoma B cell lines to paclitaxel‐induced apoptosis publication-title: Mol Cancer Ther. – volume: 90 start-page: 3844 year: 1997 end-page: 3852 article-title: Results of high‐dose therapy and autologous bone marrow/stem cell transplantation during remission in poor‐risk intermediate‐ and high‐grade lymphoma: international index high and high‐intermediate risk group publication-title: Blood. – volume: 80 start-page: 2471 year: 1992 end-page: 2478 article-title: Favorable outcome of B‐cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group publication-title: Blood. – volume: 329 start-page: 987 year: 1993 end-page: 994 article-title: A predictive model for aggressive non‐Hodgkin's lymphoma publication-title: N Engl J Med – volume: 16 start-page: 2825 year: 1998 end-page: 2833 article-title: Rituximab chimeric anti‐CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four‐dose treatment program publication-title: J Clin Oncol. – volume: 13 start-page: 1264 year: 2002 end-page: 1274 article-title: An international evaluation of CODOX‐M and CODOX‐M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study publication-title: Ann Oncol. – volume: 346 start-page: 235 year: 2002 end-page: 242 article-title: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‐B‐cell lymphoma publication-title: N Engl J Med. – volume: 34 start-page: 187 year: 1972 end-page: 220 article-title: Regression models and life tables publication-title: J R Stat Soc. – volume: 33 start-page: 451 year: 1976 end-page: 458 article-title: Proposals for the classification of the acute leukaemias publication-title: Br J Haematol. – volume: 14 start-page: 2465 year: 1996 end-page: 2472 article-title: Adult Burkitt's and Burkitt‐like non‐Hodgkin's lymphoma‐outcome for patients treated with high‐dose therapy and autologous stem‐cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation publication-title: J Clin Oncol. – volume: 53 start-page: 457 year: 1965 end-page: 481 article-title: Non‐parametric estimation from incomplete observations publication-title: J Am Stat Assoc. – volume: 19 start-page: 2153 year: 2001 end-page: 2164 article-title: Rituximab using a thrice weekly dosing schedule in B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity publication-title: J Clin Oncol 15. – volume: 14 start-page: 1960 year: 2000 end-page: 1966 article-title: De novo acute B cell leukemia/lymphoma with t(14;18) publication-title: Leukemia. – year: 1991 – volume: 9 start-page: 123 year: 1991 end-page: 132 article-title: High survival rate in advanced‐stage B‐cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children publication-title: J Clin Oncol. – volume: 8 start-page: 994 year: 1990 end-page: 1004 article-title: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard‐ and high‐risk acute lymphocytic leukemia publication-title: J Clin Oncol. – volume: 23 start-page: 4079 year: 2005 end-page: 4088 article-title: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia publication-title: J Clin Oncol. – volume: 100 start-page: 159a year: 2002 article-title: Successful treatment of Burkitt's NHL and other high‐grade NHL according to protocol for mature B‐ALL publication-title: Blood. – start-page: 152 volume-title: Malignant Lymphomas year: 2002 ident: e_1_2_5_3_2 contributor: fullname: Thomas DA – ident: e_1_2_5_7_2 doi: 10.1038/sj.leu.2401910 – ident: e_1_2_5_12_2 doi: 10.1200/JCO.1986.4.12.1732 – ident: e_1_2_5_17_2 doi: 10.1182/blood.V87.2.495.bloodjournal872495 – volume: 53 start-page: 457 year: 1965 ident: e_1_2_5_31_2 article-title: Non‐parametric estimation from incomplete observations publication-title: J Am Stat Assoc. doi: 10.1080/01621459.1958.10501452 contributor: fullname: Kaplan EL – ident: e_1_2_5_42_2 doi: 10.1200/JCO.2005.12.051 – ident: e_1_2_5_25_2 doi: 10.1056/NEJM199309303291402 – volume: 99 start-page: 264 year: 1994 ident: e_1_2_5_6_2 article-title: Cytogenetic studies on patients of acute lymphoblastic leukemia Burkitt's type with (8;14) & (14;18) translocations publication-title: Indian J Med Res. contributor: fullname: Gladstone B – volume: 34 start-page: 187 year: 1972 ident: e_1_2_5_34_2 article-title: Regression models and life tables publication-title: J R Stat Soc. contributor: fullname: Cox DR – ident: e_1_2_5_2_2 doi: 10.1182/blood-2004-02-0405 – ident: e_1_2_5_39_2 doi: 10.1200/JCO.1996.14.9.2465 – ident: e_1_2_5_5_2 doi: 10.1182/blood.V91.11.3995 – ident: e_1_2_5_22_2 doi: 10.1093/annonc/mdf253 – ident: e_1_2_5_40_2 doi: 10.1182/blood.V90.10.3844 – volume: 104 year: 2004 ident: e_1_2_5_38_2 article-title: Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) publication-title: Blood. doi: 10.1182/blood.V104.11.2732.2732 contributor: fullname: Hoelzer D – volume: 100 start-page: 159a year: 2002 ident: e_1_2_5_24_2 article-title: Successful treatment of Burkitt's NHL and other high‐grade NHL according to protocol for mature B‐ALL publication-title: Blood. contributor: fullname: Hoelzer D – volume: 2 start-page: 1183 year: 2003 ident: e_1_2_5_36_2 article-title: Rituximab (anti‐CD20) selectively modifies Bcl‐xL and apoptosis protease activating factor‐1 (Apaf‐1) expression and sensitizes human non‐Hodgkin's lymphoma B cell lines to paclitaxel‐induced apoptosis publication-title: Mol Cancer Ther. contributor: fullname: Jazirehi AR – ident: e_1_2_5_35_2 doi: 10.1111/j.1365-2141.2004.04925.x – ident: e_1_2_5_14_2 doi: 10.1200/JCO.1991.9.1.123 – ident: e_1_2_5_16_2 doi: 10.1182/blood.V80.10.2471.2471 – volume: 34 start-page: 389 year: 1992 ident: e_1_2_5_9_2 article-title: Burkitt's lymphoma in adults: a retrospective study of 46 cases publication-title: Nouv Rev Fr Hematol. contributor: fullname: Ostronoff M – volume: 8 start-page: 994 year: 1990 ident: e_1_2_5_10_2 article-title: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard‐ and high‐risk acute lymphocytic leukemia publication-title: J Clin Oncol. doi: 10.1200/JCO.1990.8.6.994 contributor: fullname: Kantarjian HM – ident: e_1_2_5_30_2 doi: 10.1002/cncr.10365 – volume: 8 start-page: 77 issue: 1 year: 1997 ident: e_1_2_5_20_2 article-title: Eighty‐one percent event‐free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol publication-title: Ann Oncol. doi: 10.1093/annonc/8.suppl_1.S77 contributor: fullname: Todeschini G – ident: e_1_2_5_28_2 doi: 10.1200/JCO.2001.19.8.2153 – ident: e_1_2_5_26_2 doi: 10.1200/JCO.1998.16.8.2825 – ident: e_1_2_5_27_2 doi: 10.1200/JCO.2001.19.8.2165 – ident: e_1_2_5_18_2 doi: 10.1200/JCO.1999.17.8.2461 – ident: e_1_2_5_23_2 doi: 10.1111/j.1365-2141.2004.05141.x – volume-title: Counting Processes and Survival Analysis year: 1991 ident: e_1_2_5_33_2 contributor: fullname: Fleming TR – ident: e_1_2_5_41_2 doi: 10.1200/JCO.2001.19.2.389 – ident: e_1_2_5_4_2 doi: 10.1111/j.1365-2141.1976.tb03563.x – ident: e_1_2_5_19_2 doi: 10.1182/blood.V85.3.664.bloodjournal853664 – ident: e_1_2_5_37_2 doi: 10.1038/sj.cdd.4400688 – volume: 5 start-page: 90 issue: 1 year: 1991 ident: e_1_2_5_8_2 article-title: Burkitt's lymphoma/leukemia: a clinicopathologic study on 24 adult patients publication-title: Leukemia. contributor: fullname: Bernasconi C – ident: e_1_2_5_11_2 doi: 10.1182/blood.V63.5.1102.1102 – ident: e_1_2_5_13_2 doi: 10.1200/JCO.1996.14.4.1252 – ident: e_1_2_5_29_2 doi: 10.1056/NEJMoa011795 – ident: e_1_2_5_21_2 doi: 10.1002/cncr.20143 – ident: e_1_2_5_15_2 doi: 10.1200/JCO.1995.13.2.359 – volume: 50 start-page: 163 year: 1966 ident: e_1_2_5_32_2 article-title: Evaluation of survival data and two new rank order statistics arising in its consideration publication-title: J R Stat Soc. contributor: fullname: Mantel N |
SSID | ssj0007253 |
Score | 2.4527566 |
Snippet | BACKGROUND
Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL.... Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL. Prognosis... Abstract BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas... |
SourceID | crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1569 |
SubjectTerms | acute lymphoblastic leukemia adult Burkitt lymphoma Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic agents Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Burkitt Lymphoma - drug therapy B‐ALL chemoimmunotherapy Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Cyclophosphamide - administration & dosage Dexamethasone - administration & dosage Doxorubicin - administration & dosage Drug Administration Schedule Female Humans hyper‐CVAD Immunotherapy Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Rituximab Survival Analysis Treatment Outcome Tumors Vincristine - administration & dosage |
Title | Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.21776 https://www.ncbi.nlm.nih.gov/pubmed/16502413 |
Volume | 106 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDqUQ0kde20cQJKeCN44trxzoJd02hEJyCEnZSzDSSCJmd72L14Ykp_6E0p_YX9KRH-ukh0Jyk21JyBpJ881I8wlgX8ZaW9-Gnibzx-Oxlp5CesQoFngUhRqrKP6z88HpFf8-ikYr8LmNhan5IZYONzczqvXaTXCpFgcdaShmmPcJUAvHt-2Y9Bwiuui4o0TQUFD6sRfxcLTkJg0OuqKPtNHaXC6oY2x9o8UDlfQQtlZ65-QVXLctro-bjPtlofp4_w-Z43N_6TWsN4CUHdcj6A2smOwtvDhrttw34LejFJilLoykCda6Y855y27Igs3__Pw1_HH8lc0n5YLlaVHeplOpGCFhRpnZ8hg7m1lWUX2wL2U-TouCyUy3aarEeYLZ5I6G1mwqGZWWWBbtG0UIn1rHJqYcm2kqN-Hq5Nvl8NRrLnLwMCR7xrPoRzIwZHnGwqBCRTiEG45k7XF76GtDGEEoown7oHWOLW0irjmZZtIeitiGW7CazTKzA8xioJFWCmsUcuTqSERCUT2S-1ZpjT3YawWazGu-jqRmZg4S171J1b092H0k6y6rGPCI1HUPtmvhd18Iyro9yB58qkT4n9qT4fnwokq9e0rm9_Cy9u-4Y0EfYLXIS_OREE-hdquR_RefGgMU |
link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSIA0cR2sXIYleEJKlyV2nT1uHVOBtQ_ThvoW2ce2iNqmVZpIjCd-AtpP3C_ZsZM2Gw9I8JaLbSU-Pj7fOfb5TMgHmWhtQxsHGt2fgCVaBgrwFngiYJ_HGnwW_3DUG5yzL2M-bvbmuFyYmh9iHXBzmuHna6fgLiC927KGQg5FFxG16N0l91DfudPLo9OWPUpEDQllmAScxeM1O2m029a9ZY82F3KJXWPrMy1uGKWbwNVbnuPH9fGqS09Y6DacTLpVqbrw8w86x__-qSfkUYNJ6UE9iJ6SOyZ_Ru4Pm1X35-TSsQrMM5dJ0uRrXVAXv6Xf0Yktrn797n87OKKLabWkRVZWP7KZVBTBMMXCdL2Tnc4t9Wwf9LAqJllZUpnr1TU24oLBdHqBo2s-kxRrS6jK1ROFIB-_jk5NNTGzTG6R8-NPZ_1B0JzlEECMLk1gIeQyMuh8JsKAAoVQhBkG6PAxuxdqgzBBKKMR_oB1sS1tONMMvTNp90Ri4xdkI5_nZptQC5EGnCysUcCAqX3BhcJ2JAut0ho65P1KoumipuxIa3LmKHXdm_ru7ZCdW8Jui4oe42ixO-RlLf32DaJZtwzZIR-9DP_Setof9U_91at_KfyOPBicDU_Sk8-jr6_Jwzrc43YJvSEbZVGZtwiASrXjh_k1uycHNA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVIqDwLy6NYghNStmnirFOJS9llVR5doYqivaDIHtsi2t3sKk2klhM_AfET-SWM89i0HJDg5iS25Xhszzdjz2eAFzLW2vo29DSZPx6PtfQU0iNGscCDKNRYRfEfTwZHp_zdNJpuwKs2Fqbmh1g73NzMqNZrN8FX2u51pKGYYd4nQC0G1-A6H4SBM71GJx15lAgaDko_9iIeTtfkpMFeV_aKOrq5kmfUM7a-0uKSTrqMWyvFM74FX9om1-dNZv2yUH389geb4__-023YbhApO6yH0B3YMNld2Dpu9tzvwU_HKbBMXRxJE611wZz3ln0lEzb_9f3H8PPhiK3m5RnL06I8TxdSMYLCjDKz9Tl2trSs4vpgr8t8lhYFk5lu01SJcwWz-QWNreVCMiotsSzaN4ogPrWOzU05M4tU3ofT8ZtPwyOvucnBw5AMGs-iH8nAkOkZC4MKFQERbjiSucftvq8NgQShjCbwg9Z5trSJuOZkm0m7L2Ib7sBmtszMQ2AWA420VFijkCNXByISiuqR3LdKa-zB81agyaom7EhqauYgcd2bVN3bg90rsu6yigGPSF_34EEt_O4LYVm3CdmDl5UI_1J7MpwMT6rUo3_J_Ay2Po7GyYe3k_eP4Ubt63FHhJ7AZpGX5imhn0LtVoP8N7g8BeM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chemoimmunotherapy+with+hyper%E2%80%90CVAD+plus+rituximab+for+the+treatment+of+adult+Burkitt+and+Burkitt%E2%80%90type+lymphoma+or+acute+lymphoblastic+leukemia&rft.jtitle=Cancer&rft.au=Thomas%2C+Deborah+A.&rft.au=Faderl%2C+Stefan&rft.au=O%27Brien%2C+Susan&rft.au=Bueso%E2%80%90Ramos%2C+Carlos&rft.date=2006-04-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=106&rft.issue=7&rft.spage=1569&rft.epage=1580&rft_id=info:doi/10.1002%2Fcncr.21776&rft.externalDBID=10.1002%252Fcncr.21776&rft.externalDocID=CNCR21776 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |